EV Parts Maker Charges Up 78% Gains

Author

Adam Garcia
March 27, 2025

​

A satellite operator is plunging after issuing weak 2025 guidance, a luxury fashion house is raising long-term targets as one of its key brands surges over 30% in sales, and an electric industrial vehicle firm maker is soaring 78% after swinging to full-year profitability.

Read on to find out more.

Uranium Sector (Sponsored)

On Behalf of Azincourt Energy Corp

A junior miner with high-grade uranium assets in Canada’s Athabasca Basin and Central Mineral Belt is making moves.

Plans are in motion, and the uranium market is heating up.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Futures 📈

What to Watch

Earnings:

  • Lululemon Athletica Inc. [LULU]: Aftermarket

  • Braze, Inc. [BRZE]: Aftermarket


  • AAR Corp. [AIR]: Aftermarket


  • Argan, Inc. [AGX]: Aftermarket


  • Infinity Natural Resources, Inc. [INR]: Aftermarket


  • Sky Harbour Group Corporation [SKYH]: Aftermarket


  • Pulse Biosciences, Inc. [PLSE]: Aftermarket

Economic Reports:

  • Initial jobless claims [March 22]: 8:30 a.m.

  • GDP (second revision) [Q4]: 8:30 a.m.

  • Advanced U.S. trade balance in goods [Feb]: 8:30 a.m.

  • Advanced retail inventories [Feb]: 8:30 a.m.

  • Advanced wholesale inventories [Feb]: 8:30 a.m.

  • Pending home sales [Feb]: 10:00 a.m.

  • Richmond Fed President Tom Barkin will speak at 4:30  p.m.

  • Boston Fed President Susan Collins will speak at 4:30 p.m.

Trading Methods (Sponsored)

Bitcoin’s ups and downs have made and lost fortunes. But what if there was a way to outperform BTC—without ever buying it?

Hedge fund titan Larry Benedict has revealed a new approach called "Bitcoin Skimming," a strategy that has outpaced Bitcoin’s returns by as much as 22-to-1.

With the SEC’s latest decision set to shake up crypto markets, now is the perfect time to discover how this works.

Communications

Telesat’s 2024 Loss Hits C$302M, Shares Plunge

Telesat (NASDAQ: TSAT) reported a tough financial year for 2024, with annual revenue dropping 19% to C$571 million ($400 M) and adjusted EBITDA sliding 28% to C$384 million ($269 M).

The company ended the year with a net loss of C$302 million. Shares of the firm are down 5.4% in premarket trade.

Despite the downturn, Telesat has secured a critical lifeline—a combined C$2.54 billion ($1.78 B) in loan commitments from the Canadian federal and Quebec provincial governments to fund its Lightspeed low-earth-orbit (LEO) satellite initiative.

The company has also completed the project’s Preliminary Design Review, moving closer to production.

Telesat’s traditional geostationary satellite (GEO) business remains steady, with a C$1.1 billion ($770M) backlog and 72% utilization across its fleet.

However, its forward guidance signals more headwinds. For 2025, Telesat expects revenue in the range of C$405 to C$425 million, and adjusted EBITDA between C$170 and C$190 million.

This is a decline of over 50% at the midpoint, largely driven by shrinking demand in North American DTH services and maritime sectors, along with growing expenses tied to its LEO infrastructure rollout.

CFO Andrew Browne is set to retire later this year, marking another transition for the company as it pivots toward next-generation connectivity services.

Luxury Fashion

Ermenegildo Zegna Raises 2027 Targets After Strong Year for Tom Ford Fashion Line

Italian luxury group Ermenegildo Zegna Group (NYSE:ZGN) announced full-year 2024 results, posting revenue of €1.95 billion, a 2.2% increase from the previous year.

Profit is at €90.9 million, down from €135.7 million in 2023, with a slimmer net margin of 4.7%.

Tom Ford Fashion led the charge with a 33.5% surge in sales, generating €314.5 million.

Meanwhile, the core ZEGNA brand reported 4.9% growth to €1.16 billion. Thom Browne sales, however, declined 16.8% year-over-year to €314.7 million.

Adjusted EBIT for the group totaled €184 million, while the gross margin improved to 66.6%.

Direct-to-consumer channels contributed 78% of total branded sales, highlighting the group’s shift toward a more vertically integrated model.

The company proposed a dividend of €0.12 per ordinary share.

Looking ahead, Zegna now forecasts revenue between €2.2 billion and €2.4 billion by 2027, with an expected adjusted EBIT range of €250 million to €300 million.

The company cites a sharpened focus on brand elevation, direct sales growth, and sustained demand for Tom Ford as key factors behind the updated outlook.

Despite profit declines, CEO Gildo Zegna emphasized the group's strategic momentum, citing continued investment in brand-building and international expansion as priorities for 2025.

Smart Screen Solutions (Sponsored)

A tech innovator could enable the mass commercialization of MicroLED displays, securing a partnership with Taiwan’s leading manufacturer.

Can this under-the-radar company follow in OLED’s footsteps?

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Pharmaceuticals

Ascentage Pharma Reports 342% Revenue Surge in 2024, Narrows Full-Year Loss

Ascentage Pharma (NASDAQ: AAPG) reported its unaudited full-year results for 2024, with annual revenue climbing 342% to $134.3 million.

The significant jump is largely driven by a $100 million payment from Takeda under an exclusive licensing agreement and strong sales of its leukemia treatment, olverembatinib, which rose 52% year-over-year in China to $33 million.

The company’s net loss narrowed to $55.6 million in 2024, a 56% improvement from the previous year.

Research and development expenses rose 34% to $129.8 million, reflecting ongoing investment in late-stage trials across its oncology pipeline.

Selling and administrative costs remained relatively stable.

Earlier this year, Ascentage completed its Nasdaq listing, raising $132.5 million.

Combined with a $75 million equity investment from Takeda and existing reserves, the company now has a $172.8 million cash position and expects to fund operations through 2027.

The company is currently running ten global Phase III trials, including FDA-cleared studies for olverembatinib in chronic myeloid leukemia and APG-2449 for lung cancer.

Lisaftoclax, another key candidate, is under priority review in China for chronic lymphocytic leukemia.

CEO Dr. Dajun Yang said that Ascentage remains focused on advancing innovative therapies and expanding access to patients globally.

With olverembatinib now fully covered under China’s national drug reimbursement program and momentum in its global trials, the company has positioned itself for further growth in 2025.

Movers and Shakers

Soleno Therapeutics, Inc. [SLNO] - Last Close: $48.97

Soleno Therapeutics is a late-stage biopharmaceutical company focused on developing treatments for rare diseases, particularly those involving metabolic and neurobehavioral disorders. Its lead asset, VYKAT XR, targets hyperphagia.

Soleno shares are surging 37% in premarket trading after the company secured FDA approval for VYKAT XR to treat hyperphagia in both adults and children with PWS.

My Take: This FDA approval is a pivotal win for Soleno, addressing a serious unmet need in PWS care. With commercial launch imminent, SLNO could see sustained momentum. Keep a close watch on this stock.

Greenland Technologies [GTEC] - Last Close: $1.31

Greenland Technologies designs and manufactures electric industrial vehicles and drivetrain systems for material-handling equipment.

Its share are soaring 78% in early trading after Greenland reported a full-year profit of $15.2 million, or $1.03 per share, compared to a loss of $1.20 per share in 2023.

My Take: Greenland's pivot to profitability despite headwinds is a strong signal of operational efficiency. If it can stabilize revenue and capitalize on the EV industrial vehicle trend, it could see positive momentum upwards. Keep this stock on your radar.

Petco Health and Wellness Company [WOOF] - Last Close: $2.44

Petco Health and Wellness is a major U.S. pet retailer offering pet food, supplies, and veterinary services.

Its shares are up 8.6% in premarket after it beat Q4 sales estimates, reporting $1.60 billion in revenue versus the $1.56 billion expected.

My Take: Petco’s focus on essential pet care services continues to support sales stability. While growth may be limited short term, its improving cost structure and market presence could appeal to value investors.

Insider Intel (Sponsored)

Every investor in America is trying to figure out what Musk will do in Washington, D.C., in the coming weeks.

One Boston-based think tank – who has studied Elon's work for decades – is stepping forward to share what they've found.

They believe his TRUE plan is far more radical than anyone realizes. It could change the way you live, work, get paid, and collect Social Security...AND could make more people rich than all of Elon's previous ventures – PUT TOGETHER.

Everything Else

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.

*Standard message/carrier rates may apply.

Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails.